放射線治療診斷劑市場－全球產業規模、佔有率、趨勢、機會及預測（按放射性同位素、應用、最終用戶、地區和競爭格局分類，2021-2031年）

全球放射治療診斷市場預計將從 2025 年的 111.5 億美元大幅成長至 2031 年的 339.8 億美元，複合年成長率為 20.41%。

診斷性放射治療，主要應用於腫瘤學領域，是精準醫療的典範，它利用成對的放射性藥物同時進行疾病的診斷和治療。全球癌症發生率的不斷攀升以及臨床上對個人化治療方法日益成長的需求，極大地推動了這個市場的發展。個人化治療方案旨在最大限度地提高療效，同時最大限度地降低全身毒性。這種雙重方法使臨床醫生能夠清楚地了解疾病的範圍，並將放射治療精準地輸送到特定的細胞位置，從而促進了其在醫療保健系統中的廣泛應用，最終改善患者的治療效果。

然而，該產業在供應鏈穩定性方面面臨嚴峻挑戰，尤其是在醫用放射性同位素的可靠供應方面。這些關鍵材料的生產嚴重依賴數量有限的老舊核子研究反應器，這使得市場極易受到計劃外運作和物流中斷的影響。根據歐洲核子醫學協會預測，2024年底意外的核子反應爐維護問題將導致關鍵診斷用同位素發生器供應短缺高達40%，凸顯了全球分銷網路的脆弱性。

市場促進因素

全球標靶化癌症發生率的上升是推動放射治療診斷市場發展的主要因素。隨著腫瘤疾病負擔的加重，醫療機構優先考慮兼具診斷準確性和治療效果的治療性診斷方式，以應對複雜的病例。需要高階治療的病例數不斷增加，也印證了對個人化治療的需求。根據美國癌症協會於2024年1月發布的《2024年癌症事實與數據》報告，預計2024年美國將新增2,001,140例癌症病例。日益成長的疾病負擔直接推動了已通過核准的放射性配體療法的商業性應用。諾華公司在2024年10月發布的《2024年第三季中期財務報告》中披露，其Pulvict療法的季度淨銷售額為3.86億美元，這凸顯了市場對這類標靶治療的巨大需求。

同時，公共和私人投資與資金籌措的激增正在改變該行業的競爭格局。大型製藥企業意識到放射性藥物的商業性可行性，正積極收購專業生物技術公司，以確保獲得專有平台和生產基礎設施。這些資金注入對於克服傳統供應鏈的脆弱性以及加速新型同位素的開發至關重要。例如，百時美施貴寶在2024年2月的新聞稿中宣布，已完成對RaiseBio的收購，總對價約41億美元。如此規模的資金注入標誌著產業正朝著擴大全球產能以滿足預期長期需求的方向做出重大轉變。

市場挑戰

全球放射治療診斷市場面臨供應鏈脆弱性帶來的重大挑戰，尤其是關鍵醫用放射性同位素的不穩定性。該行業依賴日益老化且產能下降的核子研究反應器來生產構成診斷和治療藥物基礎的同位素。這些設施的非計劃性停機或維修延誤會立即造成瓶頸，阻礙救命放射性藥物的生產。這種不可靠性迫使臨床醫生推遲或取消對時間要求嚴格的癌症治療，削弱了人們對放射治療診斷作為腫瘤學永續支柱的信心，並阻礙了醫療機構對必要基礎設施的投資。

這些物流挑戰的影響十分嚴重且可衡量。據美國核子醫學與分子影像學會稱，2024年計畫外核子反應爐停駛將導致全球供不應求50%至100%，遠低於正常需求。這些嚴重的供應中斷直接限制了市場收入，並阻礙了同位素技術的普及，因為製藥公司無法保證患者能夠獲得所需產品。因此，同位素供應的不穩定性仍然是限制該領域整體成長潛力的主要障礙。

市場趨勢

全球放射治療和診斷市場正經歷一場意義重大的技術變革，其標誌是向標靶α粒子治療（TAT）的轉型。與常見的BETA發射同位素（如鎦-177）不同，α發射體（如錒-225）能夠釋放短程、高線性能量轉移（LET）的輻射，在保護周圍健康組織的同時，還能高效地誘導雙鏈DNA斷裂，從而有效殺傷微轉移灶。這種治療方法方式的轉變促使各大製藥公司投入大量資金，以確保其專有的錒供應鏈和研發管線。例如，Astra Zeneca於2024年6月以約24億美元收購了Fusion Pharmaceuticals公司，將其基於錒的放射性標記化合物整合到其腫瘤產品組合中。

同時，業內人士注意到，一些專門從事放射性藥物CDMO（合約研發生產機構）的機構正在湧現，旨在緩解傳統生產模式的脆弱性。為了應對超短半衰期同位素帶來的物流複雜性，這些專業CDMO正在建構專門的基礎設施，以實現分散式、即時生產，而非傳統的集中式模式。這種結構性擴張對於確保商業性擴充性以及在核子反應爐停駛情況下的冗餘備份至關重要。正如Nucleus RadioPharma在2024年5月的新聞稿中所宣布的那樣，該公司宣布將新建兩座面積超過10萬平方英尺的設施，以解決全國範圍內的供應鏈瓶頸問題。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球放射線治療診斷市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依放射性同位素（Technetium-99、鎵-68、碘-131、碘-123、18F、Y-90、鎦（Lu）177、銅（Cu）67、銅（Cu）64等）
  • 依應用領域（腫瘤科與非腫瘤科）
  • 依最終用戶（醫院/診所、製藥/生技公司、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美放射線治療診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲放射線治療診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區放射線治療診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲放射線治療診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲放射線治療診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球放射線治療診斷市場：SWOT分析

第14章 波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• TransCode Therapeutics, Inc
• Curium SAS
• GE Healthcare Inc
• Bayer AG
• Lantheus Medical Imaging, Inc
• Novartis AG
• Spectrum Pharmaceuticals, Inc
• Ipsen SA
• Actinium Pharmaceuticals, Inc
• Nordic Nanovector ASA
• Y-mAbs Therapeutics, Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Radiotheranostics Market is projected to expand significantly, growing from USD 11.15 Billion in 2025 to USD 33.98 Billion by 2031, representing a CAGR of 20.41%. Radiotheranostics represents a precision medical paradigm that employs paired radiopharmaceuticals to simultaneously diagnose and treat pathologies, primarily within the field of oncology. The market is largely driven by the rising global prevalence of cancer and a growing clinical preference for personalized therapeutic regimens that maximize efficacy while minimizing systemic toxicity. This dual approach enables clinicians to visualize the extent of disease and deliver targeted radiation to specific cellular sites, thereby encouraging widespread adoption across healthcare systems aimed at improving patient outcomes.

However, the sector encounters a substantial challenge regarding supply chain stability, particularly concerning the reliable availability of medical radioisotopes. The production of these essential materials relies heavily on a limited number of aging nuclear research reactors, leaving the market exposed to unscheduled outages and logistical disruptions. According to Nuclear Medicine Europe, unexpected reactor maintenance issues in late 2024 were projected to result in supply shortages of up to 40% for critical diagnostic isotope generators, underscoring the fragility of the global distribution network.

Market Driver

The rising global incidence of targetable cancers acts as the primary catalyst driving the radiotheranostics market. As the burden of oncological disease increases, healthcare providers are prioritizing theranostic modalities that combine diagnostic precision with therapeutic lethality to manage complex cases. This demand for personalized intervention is supported by the growing volume of diagnoses requiring advanced care; according to the American Cancer Society's "Cancer Facts & Figures 2024" report from January 2024, 2,001,140 new cancer cases were projected to occur in the United States in 2024. This intensifying disease burden has directly resulted in substantial commercial uptake for approved radioligand therapies, as evidenced by Novartis reporting in their October 2024 "Q3 2024 Interim Financial Report" that net sales for the therapy Pluvicto reached $386 million for the quarter, reflecting the critical market need for these targeted treatments.

Concurrently, a surge in public-private investments and funding is transforming the sector's competitive landscape. Acknowledging the commercial viability of radiopharmaceuticals, major pharmaceutical entities are aggressively acquiring specialized biotech firms to secure proprietary platforms and manufacturing infrastructure. These capital infusions are essential for overcoming historical supply chain fragilities and accelerating the development of novel isotopes. For instance, Bristol Myers Squibb announced in a February 2024 press release that it had finalized the acquisition of RayzeBio for a total equity value of approximately $4.1 billion. This level of financial commitment signals a definitive shift toward scaling global production capabilities to meet anticipated long-term demand.

Market Challenge

The Global Radiotheranostics Market contends with a critical impediment stemming from the fragility of its supply chain, specifically the inconsistent availability of essential medical radioisotopes. The industry relies on a shrinking number of aging nuclear research reactors to produce these isotopes, which form the foundation for paired diagnostic and therapeutic agents. Any unscheduled outage or maintenance delay at these facilities creates an immediate bottleneck, preventing the manufacturing of life-saving radiopharmaceuticals. This unreliability compels clinicians to postpone or cancel time-sensitive cancer treatments, thereby eroding confidence in radiotheranostics as a sustainable pillar of oncology and discouraging healthcare institutions from investing in necessary infrastructure.

The impact of these logistical failures is acute and measurable. According to the Society of Nuclear Medicine and Molecular Imaging, unexpected reactor downtime in 2024 resulted in supply shortages ranging from 50% to 100% of normal requirements across various global regions. These severe disruptions directly limit market revenue and stall adoption rates, as pharmaceutical companies cannot guarantee product delivery to patients. Consequently, the volatility of the isotope supply remains the primary friction point hindering the sector's overall growth potential.

Market Trends

The Global Radiotheranostics Market is undergoing a significant technical evolution defined by the transition toward Targeted Alpha-Particle Therapies (TATs). Unlike prevailing beta-emitting isotopes such as Lutetium-177, alpha-emitters like Actinium-225 deliver high linear energy transfer radiation over a short range, inducing double-strand DNA breaks that are highly effective against micro-metastases while sparing surrounding healthy tissue. This shift in therapeutic modality has triggered substantial investment from major pharmaceutical entities seeking to secure proprietary actinium supply chains and pipelines. For example, AstraZeneca finalized the acquisition of Fusion Pharmaceuticals in June 2024 for a transaction value of approximately $2.4 billion to integrate actinium-based radioconjugates into its oncology portfolio.

Simultaneously, the industry is observing the emergence of Radiopharmaceutical-Specialized CDMOs designed to mitigate historical manufacturing vulnerabilities. To address the logistical complexities associated with isotopes having ultra-short half-lives, these specialized Contract Development and Manufacturing Organizations are engineering purpose-built infrastructure capable of decentralized, just-in-time production, distinct from traditional centralized models. This structural expansion is crucial for ensuring commercial scalability and redundancy against reactor outages. As reported by Nucleus RadioPharma in a May 2024 press release, the organization announced the development of two new facilities totaling over 100,000 square feet to address nationwide supply chain constraints.

Key Market Players

• TransCode Therapeutics, Inc
• Curium SAS
• GE Healthcare Inc
• Bayer AG
• Lantheus Medical Imaging, Inc
• Novartis AG
• Spectrum Pharmaceuticals, Inc
• Ipsen S.A
• Actinium Pharmaceuticals, Inc
• Nordic Nanovector ASA
• Y-mAbs Therapeutics, Inc

Report Scope

In this report, the Global Radiotheranostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Radiotheranostics Market, By Radioisotope

• Technetium-99
• Gallium-68
• Iodine-131
• Iodine-123
• 18F
• Y-90
• Lutetium (Lu) 177
• Copper (Cu) 67
• Copper (Cu) 64
• Others

Radiotheranostics Market, By Application

• Oncology
• Non-Oncology

Radiotheranostics Market, By End User

• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Others

Radiotheranostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Radiotheranostics Market.

Available Customizations:

Global Radiotheranostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Radiotheranostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
  • 5.2.2. By Application (Oncology v/s Non-Oncology)
  • 5.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Radiotheranostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Radioisotope
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Radiotheranostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Radioisotope
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Radiotheranostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Radioisotope
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Radiotheranostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Radioisotope
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Radiotheranostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Radioisotope
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Radiotheranostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Radioisotope
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Radiotheranostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Radioisotope
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Radiotheranostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Radioisotope
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Radiotheranostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Radioisotope
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Radiotheranostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Radioisotope
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Radiotheranostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Radioisotope
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Radiotheranostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Radioisotope
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Radiotheranostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Radioisotope
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Radiotheranostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Radioisotope
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Radiotheranostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Radioisotope
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Radiotheranostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Radioisotope
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Radiotheranostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Radioisotope
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Radiotheranostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Radioisotope
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Radiotheranostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Radioisotope
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Radiotheranostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Radioisotope
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Radiotheranostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Radioisotope
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Radiotheranostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Radioisotope
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Radiotheranostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Radioisotope
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Radiotheranostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Radioisotope
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Radiotheranostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. TransCode Therapeutics, Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Curium SAS
• 15.3. GE Healthcare Inc
• 15.4. Bayer AG
• 15.5. Lantheus Medical Imaging, Inc
• 15.6. Novartis AG
• 15.7. Spectrum Pharmaceuticals, Inc
• 15.8. Ipsen S.A
• 15.9. Actinium Pharmaceuticals, Inc
• 15.10. Nordic Nanovector ASA
• 15.11. Y-mAbs Therapeutics, Inc

16. Strategic Recommendations

17. About Us & Disclaimer